GlaxoSmithKline
NEWS
GlaxoSmithKline announced results from its pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.
While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
It was a busy week for clinical trial announcements. Here’s a look.
HES is a rare group of inflammatory disorders that affects approximately 20,000 people around the world.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
The experimental drug, if approved, will compete with GlaxoSmithKline’s Benlysta, which is the only new drug approved for lupus in the last 60 years.
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.
JOBS
IN THE PRESS